Apotex Corp. announced the launch of dasatinib tablets, a generic version of Sprycel®1, in the United States, with 180-days of exclusivity.
Dasatinib is a kinase inhibitor used to treat certain types of leukemia in both adults and children 1 year of age and older, including cases where previous treatment were not effective or tolerated.
"Apotex continues to deliver best-in-class product launches, supporting patients on their journey to health," said Christine Baeder, President, Apotex Corp. "As the first generic manufacturer to launch dasatinib in the United States, we are proud to provide this high-quality, cost-saving option."